Timothy Madden - Concepedia

Author

Timothy Madden

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Madden, Timothy L, T L Madden, T Madden, T. L. Madden, T. Madden, T.L. Madden, TIMOTHY MADDEN, Timothy L Madden, Timothy L. Madden, Timothy Madden

179

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Thoracic Surgery Foundation Cornell University

About

Timothy Madden is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	29	2.3K
2	Biochemistry	8	8	495
3	Engineering	4	4	150
4	Health Sciences	4	4	207
5	Natural Sciences	3	3	60

Timothy Madden

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer Christos N. Papandreou, Danai Daliani, Darrell Nix, Journal of Clinical Oncology	2004	436
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Marcos de Lima, Daniel R. Couriel, Peter F. Thall, Blood	2004	421
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Arifumi Iwamaru, Sławomir Szymański, Eiji Iwado, Oncogene Neuro-oncologyNovel InhibitorMedicineMalignant Glioma CellsApoptosis	2006	368
A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients S. Farzana Hussain, Ling-Yuan Kong, Justin Jordan, Cancer Research Signal TransducersImmunologyImmune RegulationImmunologic MechanismImmunotherapy	2007	310
Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors Roy S. Herbst, Kenneth R. Hess, Hai T. Tran, Journal of Clinical Oncology	2002	277
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Andrzej P. Kudelka, Damrong Tresukosol, Creighton L. Edwards, Journal of Clinical Oncology	1996	252
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Börje S. Andersson, Peter F. Thall, Timothy Madden, Biology of Blood and Marrow Transplantation	2002	226
Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin Roy S. Herbst, Nizar A. Mullani, Darren W. Davis, Journal of Clinical Oncology	2002	180
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Blood	2012	172
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. Frankie A. Holmes, Timothy Madden, Robert A. Newman, Journal of Clinical Oncology	1996	166

Page 1